IL18 and acute kidney injury: Most notably, there is emerging support for the use of neutrophil gelatinase‐associated lipocalin (NGAL), interleukin‐18 (IL‐18), liver‐type fatty acid‐binding protein (L‐FABP), and kidney injury molecule‐1 (KIM‐1) as AKI biomarkers.